

# Kava Report 2003

## In-Depth Investigation into EU Member States Market Restrictions on Kava Products

### Table of Content

Executive Summary

Situation Analysis **Part I**

Scientific Export Report:

Clinical Documentation of Kava-kava (*Piper methysticum*) **Part IIA**

Scientific Export Report: Pharmacological-Toxicological  
Documentation of Kava-kava (*Piper methysticum*) **Part IIB**

Expert Comments on the Decision of the German BfArM **Part III**

Further Strategies to Revoke the Kava Restrictions **Part IV**

Joerg Gruenwald, PhD, Cordula Mueller, PhD, Juergen Skrabal, MS  
Phytopharm Consulting - a unit of analyze & realize ag  
Waldseeweg 6, 13467 Berlin, Germany  
Tel. +49-30-40008100, Fax +49-30-40008500  
e-mail: jgruenwald@phytopharm.org  
www.phytopharm.org

Part I – Situation Analysis

1.	Situation analysis of kava restrictions .....	3
1.1	Chronology of worldwide actions taken against kava by regulatory authorities ..	4
1.2	Economic impact and consequences of kava restrictions.....	10
1.3	Actions undertaken by the South Pacific region and the Pacific Islands Forum Secretariat to resolve the kava crisis .....	13
1.4	Communication with kava-associated producers, traders and organizations ...	15
2.	Reference List .....	29
Appendix 1	.....	30
	Resolution by kava industry representatives at the Pacific Herbs Business Forum .....	30
	List of contacted organizations and associations.....	32
	List of contacted delegates of the Pacific Herbs Business Forum, Port Vila, Vanuatu, 18-20 February 2002.....	35
	List of contacted German pharmaceutical companies using kava .....	39

Part II A – Scientific Export Report:  
Clinical Documentation of Kava-kava (Piper methysticum)

A	Profile of Kava kava .....	3
B	Expert Report .....	5
	Introduction .....	5
1.	Problem Statement.....	6
2.	Clinical Pharmacology .....	8
	2.1 Active Ingredient.....	8
	2.2 Pharmacodynamics.....	8
	2.3 Pharmacokinetics.....	12
	2.4 Bioavailability/Bioequivalence .....	14
	2.5 Interactions.....	14
3.	Clinical Experience .....	18
	3.1 Efficacy.....	18
	3.1.1 Methods .....	18
	3.1.2 Meta-Analysis.....	18

3.1.3 Clinical Trials.....	19
3.2 Safety.....	30
Classification .....	33
Classification .....	34
4. Conclusions.....	41
4.1 Therapeutic Justification.....	41
4.2 Efficacy.....	42
4.3 Safety.....	43
4.4 Dosage.....	44
4.5 Benefit-Risk-Ratio .....	45
4.6 Expert Opinion.....	46
5. Reference List .....	47
6. Expert's CV.....	57
C Appendices.....	60
Appendix I: Detailed Case Analysis .....	60
Appendix II: Case Report Data Bank (Disk) .....	60

**Part II B – Scientific Export Report:**  
**Pharmacological-Toxicological Documentation of Kava-kava**  
**(Piper methysticum**

A Profile of kava kava .....	3
B Expert Report .....	5
1. Introduction.....	5
2. Pharmacodynamics .....	7
2.1 Active ingredients.....	7
2.2 Special pharmacodynamics .....	7
2.2.1 Sedative effects .....	7
2.2.2 Central muscular relaxant effects.....	11
2.2.3 Anticonvulsive action.....	13
2.2.4 Analgesic action.....	20
2.2.5 Effect on psychosis models.....	24
2.2.6 Effect on GABA and benzodiazepine binding sites .....	26
2.2.7 Inhibition of platelet MAO-B .....	27
2.3 General pharmacodynamics .....	28
2.4 Drug interactions.....	30
3. Pharmacokinetics .....	33

4.	Toxicity .....	35
4.1	Acute toxicity .....	35
4.2	Subacute and chronic toxicity .....	36
4.3	Fertility, embryotoxicity, and peri-/postnatal toxicity .....	37
4.4	Mutagenicity and Carcinogenicity .....	38
4.5	Local toxicity .....	38
4.6	Immunotoxicity .....	38
4.7	Studies conducted to clarify special problems: Tolerance .....	38
5.	Conclusion.....	39
5.1	Pharmacodynamics .....	39
5.2	Pharmacokinetics.....	39
5.3	Toxicity.....	40
5.4	Expert opinion.....	40
6.	References .....	43
7.	Expert's CV.....	48

## Part III – Expert Comments on the Decision of the German BfArM

1.	Introduction.....	3
2.	Comments on the evaluations of the BfArM .....	3
2.1.	Efficacy of kava preparations.....	3
2.1.1.	Comments on the efficacy .....	3
2.1.2.	Methodological Quality.....	4
2.2.	Safety of kava preparations .....	5
2.2.1.	Evaluation of case reports .....	5
2.2.2.	General safety.....	8
2.3.	Benefit-Risk-Ratio.....	9
3.	Comments on the actions of the German BfArM .....	10
3.1.	Reaction on the revised benefit-risk-ratio of the SWISSMEDIC .....	10
3.2.	Treatment of the German Commission E .....	10
3.3.	Withdrawal of market authorisation of kava preparations up a homoeopathic concentration of <u>D4</u> .....	10
3.4.	Possible alternatives to a withdrawal of market authorisation.....	11
4.	Conclusions.....	12
5.	References .....	13

## Part IV – Further Strategies to Revoke the Kava Restrictions

1.	Strategic Objectives .....	3
2.	Current Situation .....	3
2.1.	Scientific evaluation of Kava.....	3
2.2.	Special role of the German BfArM and the Swiss SWISSMEDC.....	4
3.	Strategic options.....	4
3.1.	Legal proceedings at national level .....	4
3.2.	Legal proceedings at European level.....	4
3.3.	Official complaint at the World Trade Organization (WTO).....	5
3.4.	Official request at the World Health Organization.....	5
3.5.	Providing national health authorities with new scientific data demonstrating the efficacy and safety of kava .....	5
3.6.	Claiming the differences between traditional and “European” preparations.....	6
4.	Proposal of further strategies .....	6
4.1.	Implementation of an Executive Committee .....	7
4.2.	Request for scientific re-evaluation of kava at the WHO.....	7
4.3.	Contact the Advisory Centre on WTO Law .....	7
4.4.	Possible actions against the German health authority BfArM .....	8
4.5.	Ask for support from international aid organizations.....	8
4.6.	Arouse public concern about the unjustified measures taken by health authorities .....	9

Appendix II of part IIA:

FDA Case Reports (available on CD upon request)